David J. DeGraff

3.1k total citations
69 papers, 1.8k citations indexed

About

David J. DeGraff is a scholar working on Molecular Biology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, David J. DeGraff has authored 69 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Molecular Biology, 39 papers in Surgery and 21 papers in Pulmonary and Respiratory Medicine. Recurrent topics in David J. DeGraff's work include Bladder and Urothelial Cancer Treatments (37 papers), Urinary and Genital Oncology Studies (24 papers) and Epigenetics and DNA Methylation (21 papers). David J. DeGraff is often cited by papers focused on Bladder and Urothelial Cancer Treatments (37 papers), Urinary and Genital Oncology Studies (24 papers) and Epigenetics and DNA Methylation (21 papers). David J. DeGraff collaborates with scholars based in United States, Denmark and United Kingdom. David J. DeGraff's co-authors include Robert J. Matusik, Xiuping Yu, Joshua I. Warrick, Jay D. Raman, Lauren Shuman, Matthew Kaag, Monika Joshi, Monali Vasekar, Vonn Walter and Hironobu Yamashita and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

David J. DeGraff

65 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David J. DeGraff United States	24	981	789	518	402	323	69	1.8k
Josep Domingo‐Domenech United States	19	1.2k 1.2×	402 0.5×	593 1.1×	885 2.2×	599 1.9×	46	2.1k
Kristina Lövgren Sweden	22	1.2k 1.2×	1.2k 1.5×	565 1.1×	1.0k 2.6×	583 1.8×	32	2.5k
Eri Arai Japan	30	1.5k 1.5×	326 0.4×	446 0.9×	427 1.1×	597 1.8×	78	2.2k
Shi‐Ming Tu United States	19	857 0.9×	361 0.5×	1.1k 2.1×	781 1.9×	397 1.2×	72	2.1k
Tsukasa Igawa Japan	16	481 0.5×	343 0.4×	447 0.9×	278 0.7×	191 0.6×	107	1.2k
Tatsuhiro Yoshiki Japan	21	550 0.6×	248 0.3×	314 0.6×	246 0.6×	245 0.8×	68	1.3k
Tobias Zellweger Switzerland	26	1.2k 1.3×	369 0.5×	823 1.6×	1.1k 2.7×	709 2.2×	51	2.4k
Vladimir Bilim Japan	25	1.4k 1.4×	255 0.3×	475 0.9×	583 1.5×	397 1.2×	81	2.1k
Hiroya Oka Japan	15	1.1k 1.2×	192 0.2×	350 0.7×	426 1.1×	252 0.8×	52	1.7k
Puay Hoon Tan Singapore	18	597 0.6×	261 0.3×	461 0.9×	484 1.2×	361 1.1×	41	1.4k

Countries citing papers authored by David J. DeGraff

Since Specialization

Citations

This map shows the geographic impact of David J. DeGraff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David J. DeGraff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David J. DeGraff more than expected).

Fields of papers citing papers by David J. DeGraff

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David J. DeGraff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David J. DeGraff. The network helps show where David J. DeGraff may publish in the future.

Co-authorship network of co-authors of David J. DeGraff

This figure shows the co-authorship network connecting the top 25 collaborators of David J. DeGraff. A scholar is included among the top collaborators of David J. DeGraff based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David J. DeGraff. David J. DeGraff is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yang, Sijia, Kathleen E. Mach, Guoli Chen, et al.. (2025). Microbial Product Cocktails for Personalized Cancer Immunotherapy. Nature Communications. 16(1). 10625–10625.

Lawrence, Sarah H., Hironobu Yamashita, Lauren Shuman, et al.. (2025). Interferon-γ/Janus Kinase 1/STAT1 Signaling Represses Forkhead Box A1 and Drives a Basal Transcriptional State in Muscle-Invasive Bladder Cancer. American Journal Of Pathology. 195(5). 1013–1030. 2 indexed citations

Joshi, Monika, Leonard Tuanquin, Junjia Zhu, et al.. (2023). Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023. Journal for ImmunoTherapy of Cancer. 11(2). e006551–e006551. 18 indexed citations

Shuman, Lauren, Jonathan Pham, Xue‐Ru Wu, et al.. (2023). Urothelium-Specific Expression of Mutationally Activated Pik3ca Initiates Early Lesions of Noninvasive Bladder Cancer. American Journal Of Pathology. 193(12). 2133–2143.

Joshi, Monika, Sheldon L. Holder, Junjia Zhu, et al.. (2021). Avelumab in Combination with Eribulin Mesylate in Metastatic Urothelial Carcinoma: BTCRC GU-051, a Phase 1b Study. European Urology Focus. 8(2). 483–490. 6 indexed citations

Meeks, Joshua J., Hikmat Al‐Ahmadie, Bishoy M. Faltas, et al.. (2020). Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes. Nature Reviews Urology. 17(5). 259–270. 121 indexed citations

Yamashita, Hironobu, Yuka Imamura Kawasawa, Lauren Shuman, et al.. (2019). Repression of transcription factor AP-2 alpha by PPARγ reveals a novel transcriptional circuit in basal-squamous bladder cancer. Oncogenesis. 8(12). 69–69. 23 indexed citations

DeGraff, David J., et al.. (2019). Modeling Tumor Heterogeneity in Bladder Cancer: The Current State of the Field and Future Needs. Bladder Cancer. 5(4). 251–261. 2 indexed citations

Flaig, Thomas W., Ashish M. Kamat, Donna E. Hansel, et al.. (2017). Proceedings of the 3rd Annual Albert Institute for Bladder Cancer Research Symposium. Bladder Cancer. 3(3). 211–223. 3 indexed citations

10.

Warrick, Joshua I., Matthew Kaag, Jay D. Raman, et al.. (2017). FOXA1 and CK14 as markers of luminal and basal subtypes in histologic variants of bladder cancer and their associated conventional urothelial carcinoma. Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin. 471(3). 337–345. 44 indexed citations

11.

Warrick, Joshua I., Vonn Walter, Hironobu Yamashita, et al.. (2016). FOXA1, GATA3 and PPARɣ Cooperate to Drive Luminal Subtype in Bladder Cancer: A Molecular Analysis of Established Human Cell Lines. Scientific Reports. 6(1). 38531–38531. 101 indexed citations

12.

Yamashita, Hironobu, Joshua I. Warrick, Zongyu Zheng, et al.. (2016). On a FOX hunt: functions of FOX transcriptional regulators in bladder cancer. Nature Reviews Urology. 14(2). 98–106. 32 indexed citations

13.

Kaag, Matthew, Jay D. Raman, Lauren Shuman, et al.. (2016). Clinical significance of prominent retraction clefts in invasive urothelial carcinoma. Human Pathology. 61. 90–96. 8 indexed citations

14.

Adam, Rosalyn M. & David J. DeGraff. (2015). Molecular mechanisms of squamous differentiation in urothelial cell carcinoma: A paradigm for molecular subtyping of urothelial cell carcinoma of the bladder. Urologic Oncology Seminars and Original Investigations. 33(10). 444–450. 17 indexed citations

15.

Taylor, John A., et al.. (2014). Progress made in the use of animal models for the study of high-risk, nonmuscle invasive bladder cancer. Current Opinion in Urology. 24(5). 512–516. 4 indexed citations

16.

Grabowska, Magdalena M., David J. DeGraff, Xiuping Yu, et al.. (2014). Mouse models of prostate cancer: picking the best model for the question. Cancer and Metastasis Reviews. 33(2-3). 377–397. 89 indexed citations

17.

Sterling, Julie A., James Edwards, David J. DeGraff, et al.. (2013). Activation of NF-kappa B Signaling Promotes Growth of Prostate Cancer Cells in Bone. PLoS ONE. 8(4). e60983–e60983. 65 indexed citations

18.

Choudhary, Shilpa, Poornima Hegde, James R. Pruitt, et al.. (2013). Macrophage migratory inhibitory factor promotes bladder cancer progression via increasing proliferation and angiogenesis. Carcinogenesis. 34(12). 2891–2899. 46 indexed citations

19.

Strand, Douglas W., David J. DeGraff, Ming Jiang, et al.. (2012). Deficiency in Metabolic Regulators PPARγ and PTEN Cooperates to Drive Keratinizing Squamous Metaplasia in Novel Models of Human Tissue Regeneration. American Journal Of Pathology. 182(2). 449–459. 22 indexed citations

20.

Zhang, Jianfeng, Nan Gao, David J. DeGraff, et al.. (2010). Characterization of cis elements of the probasin promoter necessary for prostate‐specific gene expression. The Prostate. 70(9). 934–951. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact